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Abstract: The heterogeneity of metastatic breast cancer mandates the need to select therapies 
taking into account tumor and patient characteristics. Chemotherapy is indicated in the palliative 
setting especially when the disease is unresponsive to hormonal therapy or is hormone-recep-
tor negative. The main chemotherapeutic agents are anthracyclines, taxanes, and capecitabine. 
The knowledge of the effects of currently approved agents and of the biology of breast cancer 
have paved the way for the evaluation of new treatment options, among which are anti-ang-
iogenic agents. Angiogenesis inhibition has resulted in clinically signiﬁ  cant improvements in 
the outcome of a variety of malignancies, including breast cancer. Bevacizumab, a monoclonal 
antibody anti-vascular endothelial growth factor (VEGF), is the most extensively studied anti-
angiogenic compound. According to the results of a phase III trial in patients with untreated 
metastatic breast cancer, bevacizumab increases both objective response rate and median 
progression-free survival when combined with standard chemotherapy vs chemotherapy alone. 
The combination of anti-angiogenic drugs and other biologic agents is also being explored in 
an attempt to improve efﬁ  cacy.  
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Introduction to ﬁ  rst-line management of breast 
cancer, advances in targeted therapies
Advanced breast cancer is still an incurable disease, the main objectives of treatment 
including life prolongation and quality improvement. Patients with metastatic disease 
that is hormone-receptor negative and HER-2 negative should be offered chemotherapy 
alone. The most commonly used cytotoxic agents are anthracyclines, taxanes, and 
capecitabine. These agents can be used as monotherapy or in combination depend-
ing on patient and disease characteristics. A 36%–41% response rate for ﬁ  rst-line 
anthracyclines has been reported (Sledge et al 2003). This is comparable with that 
for other agents, including docetaxel (Sjostrom et al 1999) (response rates 23%–42% 
in anthracycline-pretreated patients), paclitaxel (Paridaens et al 2000) (response rates 
14%–34%), and capecitabine (O’Shaughnessy et al 2001) (response rates 30%–58%). 
Probably, an aggressive combination regimen may be particularly suited to patients 
with rapidly progressing disease and/or visceral metastases. Patients with more indo-
lent disease and older patients would be more likely to beneﬁ  t from a less aggressive 
approach with a single agent. 
The therapeutic armamentarium for advanced breast cancer has recently expanded 
with the use of new biologic agents, the best studied of which is trastuzumab, 
a humanized monoclonal antibody directed against the HER-2, which is indicated 
in a subgroup of breast cancer patients who have human HER-2 gene ampliﬁ  cation. 
A randomized phase II trial reported the statistically signiﬁ  cant beneﬁ  t of adding 
trastuzumab to either combination adriamycin and cyclophosphamide (in patients who 
had not received adjuvant anthracyclines) or single agent paclitaxel for treatment in Biologics: Targets & Therapy 2007:1(1) 4
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the metastatic setting. In particular, patients receiving trastu-
zumab had improved time to progression (TTP) than those 
who did not receive it (7.4 vs 4.6 months, p < 0.001) (Slamon 
et al 2001). Furthermore, indications for trastuzumab in 
combination with chemotherapy have been recently extended 
to the adjuvant setting. In particular, trastuzumab combined 
with paclitaxel after doxorubicin and cyclophosphamide has 
been shown to improve outcome in patients with surgically 
operable HER-2 positive breast cancer (Romond et al 2005). 
However, trastuzumab resistance usually develops and this 
mandates a non-cross resistant further approach (Konecny 
et al 2006). Lapatinib, an orally active small molecule, in-
hibits the tyrosine kinase activity of both epidermal growth 
factor receptor (EGFR) and HER-2. Some early data seem 
to support lapatinib anti-tumor activity as a single agent 
in patients with HER-2 positive breast cancer with central 
nervous system metastases refractory to trastuzumab (Lin 
et al 2006). This ﬁ  nding is important because HER-2 posi-
tive tumors frequently spread to the central nervous system, 
where the tumor is sheltered from trastuzumab and most 
chemotherapeutic agents. In a phase II study of lapatinib in 
36 patients with trastuzumab-refractory metastatic breast 
cancer, 3 partial responses and 8 stable diseases were 
achieved (Blackwell et al 2005). Recently, in a phase III 
study, women with metastatic HER-2 positive breast cancer 
who had been previously treated with anthracycline, taxane, 
and trastuzumab, were randomly assigned to receive lapa-
tinib plus capecitabine or capecitabine alone. In the interim 
analysis, the hazard ratio for disease progression was 0.49 
(95% conﬁ  dence interval [CI], 0.34–0.71; p < 0.001), with 
49 events in the combination therapy group and 72 events in 
monotherapy group. The median TTP was 8.4 months and 
4.4 months, in the two arms, respectively (Geyer et al 2006). 
This study has led to the approval of lapatinib in the US for 
advanced/metastatic breast cancer overexpressing HER-2 in 
combination with capecitabine.
Pertuzumab is a humanized monoclonal antibody that 
binds to another extracellular domain of HER-2 (Spicer 2004). 
Pertuzumab inhibits the dimerization of HER, interrupting 
intracellular cell signaling and activating inﬂ  ammatory path-
ways to elucidate antibody-dependent apoptosis. Synergy 
has been shown between trastuzumab and pertuzumab in cell 
culture, which overexpresses HER-2 (Nahta et al 2004). 
Bevacizumab, a humanized monoclonal antibody against 
vascular endothelial growth factor (VEGF), is another tar-
geted therapy, which holds great promise in the treatment 
of breast cancer. The combination of bevacizumab with 
standard chemotherapeutic agents has been associated with 
only modest increases in toxicity, and the results of ongoing 
trials are, we hope, going to clarify the most appropriate use 
of these new agents. 
Review of pharmacology, mode 
of action, and pharmacokinetics 
of bevacizumab
Angiogenesis is critical to tumor growth, invasion and 
metastasis (Folkman 1995). Several humoral factors stimu-
late this process either by inducing the enzymatic breakdown 
of the perivascular basement membrane or by inducing che-
motaxis of endothelial cells. Many malignant cells produce 
VEGF, which serves as an autocrine factor for induction, 
proliferation, and migration of vascular endothelial cells. 
These activities are mediated through the two receptors for 
VEGF, ﬂ  t-1, and KDR, which are found predominantly on 
vascular endothelial cells (Ferrara 1992) (Fig. 1). Hypoxia 
is a key signal for the induction of angiogenesis; hypoxia-
inducible factors (HIF-1 and HIF-2) are heterodimeric 
transcription factors consisting of α and β subunits. The β 
subunit is constitutively expressed while the α subunit is 
protected from degradation only under hypoxic conditions 
(Salceda and Caro 1997). VEGF has also been implicated 
in oncogenesis, through mutual regulation of the VEGF 
gene by tumor suppressor genes and dominant transforming 
oncogenes, such as von Hippel-Lindau (VHL) (Siemeister 
et al 1996; Chiarugi et al 1998).
Several studies have demonstrated a correlation between 
high levels of VEGF and increased risk of metastatic disease 
and overall poor prognosis in a variety of cancers, such as 
non small lung cancer (NSCLC), renal cancer, and breast 
cancer (Ranieri et al 2006). In particular, clinical-pathologic 
correlations also conﬁ  rm the central role of angiogenesis 
in breast cancer progression (Schneider and Miller 2005). 
HIF-α expression is associated with increased proliferation 
and expression of the estrogen receptor and VEGF (Bos 
et al 2001). VEGF production occurs early in breast cancer 
and is expressed at high levels in ductal carcinoma in situ 
(Brown et al 1995). Moreover, microvessel density (MVD) 
was shown to be higher in invasive breast cancers, associ-
ated with a shorter relapse-free and overall survival in both 
node-positive and node-negative cancers (Gasparini et al 
1997, 1999), and, ﬁ  nally, predictive for therapeutic failure 
with both hormonal therapy and chemotherapy (Foekens 
et al 2001). VEGF expression has also been quantiﬁ  ed via 
immnunohistochemistry in breast cancer specimens and a 
correlation with a poorer outcome has been observed. Biologics: Targets & Therapy 2007:1(1) 5
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The use of anti-VEGF antibodies has been extensively 
studied in preclinical in vivo models and a dose-dependent 
inhibition of tumor growth has been demonstrated (Kim et al 
1993). Furthermore, a synergistic anti-tumor activity can be 
seen when bevacizumab is administered in conjunction with 
cisplatin (Kabbinavar et al 1995). Bevacizumab is approved 
in the US and Europe for the ﬁ  rst-line treatment of metastastic 
colorectal cancer when given in combination with ﬂ  uorouracil 
and irinotecan, based on the demonstration of an overall sur-
vival beneﬁ  t over standard chemotherapy alone (Hurwitz et al 
2004). A number of phase I/II/III clinical studies in several 
cancers have then been undertaken. Bevacizumab has activity 
as a single agent in patients with previously treated metastatic 
breast cancer, inducing a 10% response rate (Cobleigh et al 
2003); this single-agent activity suggests two mechanisms of 
action: namely a cytotoxic and a cytostatic effect. 
The pharmacokinetic proﬁ  le of bevacizumab was investi-
gated in a phase I study, in which 25 patients with metastatic 
cancer who had failed prior therapies were treated at doses 
ranging from 0.1 to 10 mg/kg on days 0, 28, 35, and 42, 
administered by a 90-minute intravenous infusion. Maximum 
concentration values ranged from 2.8 to 284 μg/mL. The 
half-life was 21 days following a single dose of bevacizumab. 
Overall, the pharmacokinetics proﬁ  le indicates that when 
bevacizumab was administered once followed by a 28-day 
washout period and then weekly for 3 weeks at doses rang-
ing from 0.1 to 10 mg/kg, the disposition was characterized 
by a low clearance and a volume of distribution consistent 
with limited extravascular distribution (Gordon et al 2001). 
Serum VEGF concentrations were also evaluated in this 
study. Although increases in serum total VEGF concentration 
were seen, this was likely a result of an increase in VEGF 
synthesis/distribution, a decrease in VEGF clearance caused 
by complex formation between VEGF and bevacizumab, or 
both. Furthermore, free serum VEGF concentrations were 
found to be reduced and, at doses of  0.3 mg/kg, were below 
Figure 1 A simpliﬁ  ed scheme of the VEGF/VEGFR pathway. The development of blood vessels is regulated by production of several growth factors, such as TGF-α and 
VEGF, that are secreted by cancer cells to stimulate normal endothelial cell growth through paracrine mechanisms. VEGF binds to two different receptors: VGFR-1 (ﬂ  t-1) 
and VEGFR-2 (ﬂ  k/KDR). VEFG is a potent and speciﬁ  c mitogen for endothelial cells, activates angiogenesis and enhances vascular permeability.
Abbreviations: VEGF, vascular endothelial growth factor; TGF-α, transforming growth factor-α; VEGFR-1, vascular endothelial growth factor receptor-1; VEGFR-2, vascular 
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the detectable limit of the assay after the administration of 
bevacizumab and remained undetectable for the duration of 
the study. Based on these data, a phase Ib study was con-
ducted to achieve sustained exposure to the antibody when it 
was given weekly for 8 weeks concurrently with 2 cycles of 
standard chemotherapy administered every 28 days (doxo-
rubicin or carboplatin plus paclitaxel) or weekly for 6 out of 
8 weeks (ﬂ  uorouracil plus leucovorin). No pharmacokinetic 
interaction between bevacizumab and any of the concomitant 
chemotherapy regimens was observed. The concentration-
time proﬁ  les were consistent with those seen in the former 
study. The mean terminal half-life of bevacizumab was 13 
days (Margolin et al 2001).
Efﬁ  cacy studies, combination 
studies
The initial phase I/II trial of bevacizumab as a single agent in 
75 patients who had progressed on at least one standard treat-
ment for metastatic breast cancer has been reported (Cobleigh 
et al 2003). Objective responses were achieved, including 
one conﬁ  rmed complete response and four conﬁ  rmed partial 
responses. The overall response rate was 9.3% and median 
duration of conﬁ  rmed response was 5.5 months (range, 2.3 to 
13.7 months). At the ﬁ  nal tumor assessment, 16% of patients 
achieved stable disease or an ongoing response (Cobleigh 
et al 2003). 
A number of trials using bevacizumab with chemotherapy 
have been reported. Preclinical models of combination of 
bevacizumab and docetaxel demonstrate synergistic sup-
pression of capillary vessel formation. Based upon these 
data, 21 patients with inﬂ  ammatory and locally advanced 
breast cancer were treated with bevacizumab for cycle 1 
(15 mg/kg on day 1) followed by 6 cycles of bevacizumab 
with doxorubicin (50 mg/m2) and docetaxel (75 mg/m2) 
every 3 weeks. After locoregional therapy, patients received 
8 cycles of bevacizumab alone and hormonal therapy when 
indicated. A median decrease of 66.7% in phosphorylated 
VEGFR in tumor cells (p = 0.004) and a median increase 
of 128.9% in tumor apoptosis (p = 0.0008) were seen after 
bevacizumab alone. These changes persisted with the addi-
tion of chemotherapy (Wedam et al 2006). All 21 patients 
were assessed for response; no complete responses were 
observed, while 14 patients had a clinical partial response 
for an overall response rate of 67% (95% CI, 43%–85.4%). 
Five patients had stable disease and 2 patients had progressive 
disease. Another randomized phase II trial was conducted in 
49 patients to evaluate the vascular effects on tumor regres-
sion with combination bevacizumab/docetaxel vs docetaxel 
alone in the treatment of locally advanced breast cancer. 
Seven complete clinical responses were achieved while 32 
partial responses and 5 disease progressions were reported. 
Out of the 37 patients who underwent surgery, the median 
number of pathologically positive lymph nodes was 1 while 
43% had negative lymph nodes (Lyons et al 2006). 
The combination of weekly docetaxel (35 mg/m2) plus 
bevacizumab (10 mg/kg on days 1 and 15) was tested in 
27 patients with advanced breast cancer as ﬁ  rst- or second-
line therapy (Ramaswamy et al 2006). The overall response 
rate was 52 % with 14 partial responses and 9 stable diseases; 
the median response duration was 6.0 months (95% CI, 
4.6–6.5 months), and the median progression-free survival 
was 7.5 months (95% CI, 6.2–8.3 months). Pretreatment 
E-selectin, required for the antiangiogenic activity of end-
ostatin, was signiﬁ  cantly associated with response after 
controlling for performance status (odds ratio [OR], 1.6; 
95% CI, 1.0-2.5; p = 0.05), age (OR, 1.6; 95% CI, 1.0–2.6; 
Table 1  Phase III combination studies of bevacizumab
Patient population  Metastatic breast cancera  Metastatic breast cancerb
N. patients  680  462
  Arm 1  Arm 1
  Paclitaxel: 90 mg/m2 on days 1, 8, 15  Capecitabine: 2500 mg/m2/day for
     14 out of 21 days
  Arm 2  Arm 2
Schedule  Paclitaxel: 90 mg/m2 on days 1, 8, 15  Capecitabine: 2500 mg/m2 /day for
  Bevacizumab:10 mg/kg on days 1, 15  14 out of 21 days
     Bevacizumab:15 mg/kg q 3 weeks
Efﬁ  cacy endpoints  Response rate: 14.2% (arm 1) vs
  28.2% (arm 2); p < 0.0001  Response rate: 9.1% (arm 1) vs 
    19.8% (arm 2); p = 0.001
  Progression-free survival:  Progression-free survival:
  6.11 (arm 1) vs 10.97 (arm 2) months  4.86 (arm 1) vs 4.17 (arm 2) months
aMiller et al (2005b); bMiller et al (2005a).Biologics: Targets & Therapy 2007:1(1) 7
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p = 0.05), estrogen receptor negativity (OR, 1.8; 95% CI, 
1.0–3.0; p =  0.04), and disease-free interval (OR, 1.6; 95% 
CI, 1.0–2.5; p = 0.05). Likewise, the decrease in E-selectin 
after cycle 1 persisted after controlling for performance status 
(OR, 0.1; 95% CI, 0.0–0.9; p = 0.04), age (OR, 0.1; 95% CI, 
0.0–0.9; p = 0.04), estrogen receptor negativity (OR, 0.1; 95% 
CI, 0.0–0.8; p = 0.04), visceral disease (OR, 1.0; 95% CI, 
0.0–1.0; p = 0.04), and disease-free interval (OR, 0.1; 95% 
CI, 0.1–0.9; p = 0.03). Preclinical data supporting the role of 
E-selectin in angiogenesis, coupled with preliminary results 
of current trials, justify larger prospective studies evaluating 
E-selectin as a marker of response to bevacizumab-containing 
therapy.
The above activity results were also confirmed by 
phase III trials in heavily pretreated breast cancer patients, 
which demonstrated a signiﬁ  cant increase in objective re-
sponses with the addition of bevacizumab to chemotherapy 
while improvement in progression-free survival was not 
always observed (Table 1). In particular, results from the 
E2100 study (paclitaxel vs paclitaxel plus bevacizumab) 
as ﬁ  rst-line therapy in metastatic breast cancer showed a 
signiﬁ  cant increase in objective response rate (14.2% vs 
28.2%; p < 0.0001) and progression-free survival (6.11 vs 
10.97 months; p < 0.001) with the addition of bevacizumab 
(Miller et al 2005b). In another phase III study, 462 patients 
were treated with capecitabine (2500 mg/m2/day for 14 out 
of 21 days) with or without bevacizumab (15 mg/kg every 
3 weeks). Adding bevacizumab to capecitabine increased the 
objective response rate (19.8 vs 9.1%, p = 0.001), although 
it did not affect progression-free (4.86 vs 4.17 months) or 
overall survival (15.1 vs 14.5 months) (Miller et al 2005a). 
Based on the promising response rates of these studies, 
and the increase in progression-free survival seen in E2100 
trial, it would seem reasonable to extend the study of these 
combinations to the adjuvant setting. 
In vitro studies have demonstrated that HER-2 signaling 
increased HIF-1α protein synthesis rather than inhibited its 
degradation; this represents a novel mechanism for the regu-
lation of HIF-1 and VEGF expression (Laughner et al 2001). 
Moreover, in another preclinical study, exposure to trastuzu-
mab signiﬁ  cantly decreased VEGF in HER-2 overexpressing 
cells (Epstein et al 2002). In vivo experiments have shown 
reduction in xenograft volume using a combination of trastu-
zumab and bevacizuamb compared with single-agent control 
(Epstein et al 2002). Furthermore, the association between 
HER-2 and VEGF predict clinical outcome in primary breast 
cancer (Konecny et al 2004). Taken together, these data sup-
port the use of combination therapies directed against both 
HER-2 and VEGF for treatment of breast cancers with HER-2 
overexpression. Recently, a phase I trial of bevacizumab (at 
doses of 3, 5, or 10 mg/kg every 14 days) with trastuzumab 
(4 mg/kg loading dose, then 2 mg/kg weekly until progres-
sion) was reported. Preliminary response assessment in 9 
patients was 1 complete response, 4 partial responses, and 2 
stable diseases (Pegram et al 2004).
Preliminary data also suggest that estrogen modulates 
VEGF-induced angiogenesis in physiologic and pathologic 
conditions. Estrogen-induced VEGF expression may promote 
breast cancer growth. Therefore, combination therapy with an 
aromatase inhibitor and bevacizumab may be more effective 
than either agent alone. Preliminary data of the combination 
of letrozole (2.5 mg daily) and bevacizumab (15 mg/kg i.v. 
every 3 weeks) show satisfactory tolerability (Traina et al 
2005). 
There is also a rationale to support simultaneous block-
ade of VEGF and EGFR pathways. EGFR can transactivate 
VEGF promoter via a PI3K dependent pathway (Maity et al 
2000 and Clarke et al 2001). Moreover, several studies have 
demonstrated that blockade of the EGFR pathway results in 
an antiangiogenic effect (Bruns et al 2000). An increased 
production of VEGF could represent one possible mecha-
nism by which tumor cells escape anti-EGFR monoclonal 
antibody therapy (Viloria-Petit et al 2001). A study has tested 
the strategy of combining bevacizumab and erlotinib, an 
EGFR-tyrosine kinase inhibitor, in metastatic breast cancer. 
This combination demonstrated activity which was related to 
circulating endothelial and tumor cells (Rugo et al 2004). 
Safety and tolerability
A phase I/II dose escalation trial of bevacizumab (ranging 
from 3 to 20 mg/kg) (Cobleigh et al 2003) evaluated the safety 
proﬁ  le of the compound. Eighteen patients were treated at 
3 mg/kg, 41 at 10 mg/kg, and 16 at 20 mg/kg, every other 
week. The ﬁ  rst infusion was given over 90 minutes. If there 
were no infusion-related adverse events, the second infusion 
could be given over 60 minutes and subsequent infusions 
over 30 minutes. Overall, serious adverse events occurred in 
15 out of 75 patients. In particular, 5 cases of hypertension 
were reported as serious adverse events (3 at 3 mg/kg, 1 at 
10 mg/kg, 1 at 20 mg/kg), including 1 case of hypertensive 
encephalopathy in a patients without history of hypertension. 
Two patients developed suclavian/axillary vein thrombosis 
which resolved with anticoagulation therapy. Other 2 patients 
treated at 20 mg/kg developed headache with nausea and 
vomiting that was reported as serious. The symptoms de-
veloped 1–3 days after bevacizumab infusions, responded to Biologics: Targets & Therapy 2007:1(1) 8
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dexamethasone, and were not correlated with hypertension 
or brain metastases. Congestive heart failure was reported in 
2 patients, at doses of 10 and 20 mg/kg, respectively. Both 
patients had previously received doxorubicin at cumulative 
doses of 240 and 300 mg/m2. Thirty-nine percent of patients 
had an adverse event on the ﬁ  rst 2 days after the ﬁ  rst dose 
of bevacizumab, but all events were grade 1–2 except for 1 
case of grade 3 myalgia. No signiﬁ  cant bleeding episodes 
were reported, and this was not in keeping with that seen in 
patients with NSCLC (Sandler et al 2006). In fact, bleeding 
occurred in 25.3% of patients and never exceeded grade 1. 
Another common adverse event was hypertension, which 
occurred in 15 of 75 patients and required medical treatment 
in 14. Four of 17 patients who developed hypertension also 
had  grade 2 proteinuria at some point during the study, 
including one patient who developed nephrotic syndrome. 
Furthermore,  grade 1 proteinuria was documented in 17 of 
72 evaluated patients. The mechanism of this adverse event 
has not been fully determined, but it is likely correlated to 
glomerular damage, given the predominance of albumin 
in the urine and the presence of membranoproliferative 
glomerulonephritis in the renal biopsy in 1 patient enrolled 
in this study. VEGF is constitutively expressed in the glom-
erulus, and glomerular endothelial repair may be mediated 
though VEGF (Ostendorf et al 1999). It is possible that low 
erythropoietin levels in cancer patients may worsen the 
situation because erythropoietin stimulates VEGF release 
in the glomerulus (Alvarez et al 1998). Hemoptysis was 
not reported, despite the fact that 28% of patients had lung 
metastases at the time of study enrolment. However, the high 
incidence of headache associated with nausea and vomiting 
at the dose of 20 mg/kg, suggested that 10 mg/kg every 2 
weeks is the recommended dose. 
In the phase III E2100 study, the main toxicities were 
grade 3 hypertension (in 13% of patients) and proteinuria (in 
2.5% of patients). These two side-effects were never observed 
in the single-agent paclitaxel arm (Miller et al 2005b). In 
the other phase III study (capecitabine vs capecitabine plus 
bevicizumab), no signiﬁ  cant differences were found in the 
incidence of diarrhea, hand-foot syndrome, thromboembolic 
events, or serious bleeding episodes between the two treat-
ment groups. Only grade 3–4 treatment-requiring hyperten-
sion was more frequent in patients receiving bevacizumab 
(17.9% vs 0.5%) (Miller et al 2005a). 
The previously mentioned association between bevaci-
zumab and trastuzumab was associated with grade 1/2 toxici-
ties which included diarrhea, fatigue, and nausea. A single 
grade 2 allergic reaction, one grade 2 hypertension, and one 
grade 2 proteinuria were also observed. No patients had left 
ventricular ejection failure (Pegram et al 2004).
Patient-focused perspectives such 
as quality of life, patient satisfaction/
acceptability
In the previously mentioned E2100 study, the Functional 
Assessment of Cancer Therapy Breast (FACT-.B) was 
administered to trial participants at baseline and at weeks 
17 and 33 to assess breast cancer-speciﬁ  c symptoms and 
concerns, and overall health-related quality of life (HRQL). 
The FACT-B was completed by 610 patients at baseline, 481 
at 17 weeks, and 356 at 33 weeks. There was insufﬁ  cient 
evidence to conclude that patients receiving bevacizumab 
in addition to paclitaxel differed on self-reported symptom 
burden and HRQL with respect to those receiving paclitaxel 
alone. Bevacizumab signiﬁ  cantly improved clinical outcome 
without compromising HRQL and this reinforces the idea 
that a survival advantage can be obtained without quality of 
life impairment (Wagner et al 2006).
In the other phase III study (capecitabine vs capecitabine 
plus bevacizumab), the FACT-B questionnaire was admin-
istered at baseline, every 6 weeks until 24 weeks, and then 
every 9 weeks. Time to deterioration in quality of life (TDQ), 
as measured by the Trial Outcome Index (TOI), was the pri-
mary end point. TOI is the sum of the physical well-being, 
functional well-being, and breast cancer-speciﬁ  c questions in 
the FACT-B. A decline in TOI of more than 5 points from 
baseline, disease progression, or death were considered a 
clinically meaningful deterioration in quality of life. A total of 
370 subjects (176 in the control arm, 194 in the experimental 
arm) completed baseline, and at least 1 subsequent quality of 
life assessment. Time to deterioration in quality of life did 
not differ between treatment groups (2.86 vs 2.92 months; 
p = 0.633). Overall survival (15.1 vs 14.5 months) and time to 
deterioration in quality of life as measured by FACT-B were 
comparable in both treatment groups (Miller et al 2005a).
Conclusion, place in therapy
The main challenge in the use of bevacizumab and other bio-
logic therapies in advanced breast cancer is clearly identifying 
predicting factors, which may drive therapy appropriately. 
Correlation studies of outcome and tumor VEGF expres-
sion or VEGF receptor expression, are currently underway. 
Hopefully, these studies may provide help in understanding 
the mechanism of anti-VEGF therapy and will be helpful 
to optimize the use of anti-angiogenic agents. However, in Biologics: Targets & Therapy 2007:1(1) 9
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colorectal cancer, where bevacizumab has shown a signiﬁ  -
cant beneﬁ  t in randomized trials, tumor VEGF levels do not 
appear to be correlated with outcome. Therefore, the activ-
ity of bevacizumab may relate to something more complex 
than simply the presence or absence of VEGF in the tumor. 
An interesting question is whether the use of more or less 
selective inhibitors will be the best strategy. A ﬁ  nal major 
challenge is the identiﬁ  cation of markers that accurately pre-
dict whether patients are good candidates for this treatment 
approach. Hypertension is known to be the most frequent 
bevacizumab side-effect; to the best of our knowledge, no 
studies are evaluating hypertension as a predictive marker 
of response. This would be a novel approach potentially able 
to provide us with some new insights. 
The combination of bevacizumab with standard che-
motherapeutic agent has been associated with only modest 
increases in toxicity. Minimizing toxicity while improving 
response rate and time to progression will be an important 
goal in the effort to convert metastatic breast cancer into a 
somehow chronic, manageable disease. 
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